NCT03621982 · STUDY IN CONTEXT

Study of ADCT-301 in Patients With Selected Advanced Solid Tumors

Draft scope assessment: unclear. Attached because the study's own record describes locally advanced disease. The study was not selected for this indication by its sponsor, and its eligibility has not been reconciled against this page in full. Found by searching ClinicalTrials.gov for this cancer type, restricted to studies that have posted results to the registry. No FDA notice, FDA label or NCI summary held by this site cites this study. Because the search asked for posted results, studies without posted results were never looked for, so their absence from this page means nothing.

Read the full study record and all posted results →

Linked outcomes

Measures are not ranked. Open each original source section for treatment groups, denominators, units and results.

primary · POSTED

An adverse event (AE) is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product, which does not necessarily have to have a causal relationship with this treatment. A TEAE is defined as an AE that occurs or worsens in the period extending from the first dose of study drug to 30 days after the last dose of study drug in this study or start of a new anticancer therapy, whichever is earlier. Any clinically significant changes from baseline in the safety laboratory values, vital signs, 12-lead electrocardiogram (ECG), and Eastern Cooperative Oncology Group (ECOG) performance status were reported as TEAEs.

Safety Analysis Set: The Safety analysis set consists of all participants who received study drug.

→

primary · POSTED

AEs were graded according to CTCAE v4.0 (or more recent). For events not included in the CTCAE criteria, the severity of the AE was graded on a scale of 1 to 5, where 1 is asymptomatic or mild symptoms, 2 is moderate, 3 is severe, 4 is Life-threatening consequences and 5 is death related to an AE.

Safety Analysis Set: The Safety analysis set consists of all participants who received study drug and experienced TEAEs only.

→

primary · POSTED

A SAE is defined as any AE that results in death, is life threatening, requires inpatient hospitalization or prolongation of existing hospitalization (hospitalization for elective procedures or for protocol compliance is not considered an SAE), results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or important medical events that do not meet the preceding criteria but based on appropriate medical judgement may jeopardize the participant or may require medical or surgical intervention to prevent any of the outcomes listed above.

Safety Analysis Set: The Safety analysis set consists of all participants who received study drug.

→

primary · POSTED

AEs were graded according to CTCAE v4.0 (or more recent). For events not included in the CTCAE criteria, the severity of the AE was graded on a scale of 1 is mild or asymptomatic, 2 is moderate, 3 is severe, 4 is Life-threatening and 5 is death related to an AE.

Safety Analysis Set: The Safety analysis set consists of all participants who received study drug. Analysis only included participants with SAEs.

→

primary · POSTED

Dose interruption for participants treated with ADCT-301 as monotherapy and for participants treated with ADCT-301 in combination with pembrolizumab.

Safety Analysis Set: The Safety analysis set consists of all participants who received study drug.

→

primary · POSTED

Dose reductions for participants treated with ADCT-301 as monotherapy and for participants treated with ADCT-301 in combination with pembrolizumab.

Safety Analysis Set: The Safety analysis set consists of all participants who received study drug.

→

Reported safety

Serious events are not the same as severe events. Compare the original safety groups and their at-risk populations.

Open the study safety table →

Quality of life and patient-reported measures

No linked quality-of-life measure is recorded for this setting and study.

Full draft applicability and source-link record

trial

release id: clinical-indications-draft-1
disease state id: ds-pancreatic-cancer-locally-advanced-06747430
nct id: NCT03621982
trial label: Study of ADCT-301 in Patients With Selected Advanced Solid Tumors
applicability: unclear
applicability note: Attached because the study's own record describes locally advanced disease. The study was not selected for this indication by its sponsor, and its eligibility has not been reconciled against this page in full.
curation status: draft
reviewed by: Source null
reviewed at: Source null
created at: 2026-09-10T00:00:00Z
provenance class: registry-condition-search
discovery note: Found by searching ClinicalTrials.gov for this cancer type, restricted to studies that have posted results to the registry. No FDA notice, FDA label or NCI summary held by this site cites this study. Because the search asked for posted results, studies without posted results were never looked for, so their absence from this page means nothing.
outcome Count: 6
harms Count: 14
qol Count: 0

outcomes

release id
clinical-indications-draft-1
disease state id
ds-pancreatic-cancer-locally-advanced-06747430
nct id
NCT03621982
outcome key
om-0000
source section id
NCT03621982-om-0000
source outcome index
0
endpoint
Number of Participants Who Experienced Treatment-emergent Adverse Events (TEAEs)
endpoint definition
An adverse event (AE) is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product, which does not necessarily have to have a causal relationship with this treatment. A TEAE is defined as an AE that occurs or worsens in the period extending from the first dose of study drug to 30 days after the last dose of study drug in this study or start of a new anticancer therapy, whichever is earlier. Any clinically significant changes from baseline in the safety laboratory values, vital signs, 12-lead electrocardiogram (ECG), and Eastern Cooperative Oncology Group (ECOG) performance status were reported as TEAEs.
time origin
Up to 3 years
analysis role
primary
reporting status
POSTED
data cutoff
Source null
population note
Safety Analysis Set: The Safety analysis set consists of all participants who received study drug.
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
release id
clinical-indications-draft-1
disease state id
ds-pancreatic-cancer-locally-advanced-06747430
nct id
NCT03621982
outcome key
om-0001
source section id
NCT03621982-om-0001
source outcome index
1
endpoint
Number of Participants Who Experienced TEAEs by Common Terminology Criteria for Adverse Events (CTCAE) Grade
endpoint definition
AEs were graded according to CTCAE v4.0 (or more recent). For events not included in the CTCAE criteria, the severity of the AE was graded on a scale of 1 to 5, where 1 is asymptomatic or mild symptoms, 2 is moderate, 3 is severe, 4 is Life-threatening consequences and 5 is death related to an AE.
time origin
Up to 3 years
analysis role
primary
reporting status
POSTED
data cutoff
Source null
population note
Safety Analysis Set: The Safety analysis set consists of all participants who received study drug and experienced TEAEs only.
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
release id
clinical-indications-draft-1
disease state id
ds-pancreatic-cancer-locally-advanced-06747430
nct id
NCT03621982
outcome key
om-0002
source section id
NCT03621982-om-0002
source outcome index
2
endpoint
Number of Participants Who Experienced Treatment-emergent Serious Adverse Events (SAEs)
endpoint definition
A SAE is defined as any AE that results in death, is life threatening, requires inpatient hospitalization or prolongation of existing hospitalization (hospitalization for elective procedures or for protocol compliance is not considered an SAE), results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or important medical events that do not meet the preceding criteria but based on appropriate medical judgement may jeopardize the participant or may require medical or surgical intervention to prevent any of the outcomes listed above.
time origin
Up to 3 years
analysis role
primary
reporting status
POSTED
data cutoff
Source null
population note
Safety Analysis Set: The Safety analysis set consists of all participants who received study drug.
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
release id
clinical-indications-draft-1
disease state id
ds-pancreatic-cancer-locally-advanced-06747430
nct id
NCT03621982
outcome key
om-0003
source section id
NCT03621982-om-0003
source outcome index
3
endpoint
Number of Participants Who Experienced a SAE by CTCAE Grade
endpoint definition
AEs were graded according to CTCAE v4.0 (or more recent). For events not included in the CTCAE criteria, the severity of the AE was graded on a scale of 1 is mild or asymptomatic, 2 is moderate, 3 is severe, 4 is Life-threatening and 5 is death related to an AE.
time origin
Up to 3 years
analysis role
primary
reporting status
POSTED
data cutoff
Source null
population note
Safety Analysis Set: The Safety analysis set consists of all participants who received study drug. Analysis only included participants with SAEs.
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
release id
clinical-indications-draft-1
disease state id
ds-pancreatic-cancer-locally-advanced-06747430
nct id
NCT03621982
outcome key
om-0004
source section id
NCT03621982-om-0004
source outcome index
4
endpoint
Number of Participants Who Experienced a Dose Interruption
endpoint definition
Dose interruption for participants treated with ADCT-301 as monotherapy and for participants treated with ADCT-301 in combination with pembrolizumab.
time origin
Up to 3 years
analysis role
primary
reporting status
POSTED
data cutoff
Source null
population note
Safety Analysis Set: The Safety analysis set consists of all participants who received study drug.
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
release id
clinical-indications-draft-1
disease state id
ds-pancreatic-cancer-locally-advanced-06747430
nct id
NCT03621982
outcome key
om-0005
source section id
NCT03621982-om-0005
source outcome index
5
endpoint
Number of Participants Who Experienced a Dose Reduction
endpoint definition
Dose reductions for participants treated with ADCT-301 as monotherapy and for participants treated with ADCT-301 in combination with pembrolizumab.
time origin
Up to 3 years
analysis role
primary
reporting status
POSTED
data cutoff
Source null
population note
Safety Analysis Set: The Safety analysis set consists of all participants who received study drug.
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z

arms

release id
clinical-indications-draft-1
disease state id
ds-pancreatic-cancer-locally-advanced-06747430
nct id
NCT03621982
outcome key
om-0000
arm key
OG000
arm label
ADCT-301 Monotherapy 20 µg/kg
regimen
Participants received 20 µg/kg ADCT-301 Q3W, IV infusion on Day 1 of each 21-day cycle.
analyzed count
3
analyzed unit
Participants
is comparator
Source null
source pointer
NCT03621982-om-0000#groups/OG000
release id
clinical-indications-draft-1
disease state id
ds-pancreatic-cancer-locally-advanced-06747430
nct id
NCT03621982
outcome key
om-0000
arm key
OG001
arm label
ADCT-301 Monotherapy 30 µg/kg
regimen
Participants received 30 µg/kg ADCT-301 Q3W, IV infusion on Day 1 of each 21-day cycle.
analyzed count
5
analyzed unit
Participants
is comparator
Source null
source pointer
NCT03621982-om-0000#groups/OG001
release id
clinical-indications-draft-1
disease state id
ds-pancreatic-cancer-locally-advanced-06747430
nct id
NCT03621982
outcome key
om-0000
arm key
OG002
arm label
ADCT-301 Monotherapy 45 µg/kg
regimen
Participants received 45 µg/kg ADCT-301 Q3W, IV infusion on Day 1 of each 21-day cycle.
analyzed count
5
analyzed unit
Participants
is comparator
Source null
source pointer
NCT03621982-om-0000#groups/OG002
release id
clinical-indications-draft-1
disease state id
ds-pancreatic-cancer-locally-advanced-06747430
nct id
NCT03621982
outcome key
om-0000
arm key
OG003
arm label
ADCT-301 Monotherapy 60 µg/kg
regimen
Participants received 60 µg/kg ADCT-301 Q3W, IV infusion on Day 1 of each 21-day cycle.
analyzed count
5
analyzed unit
Participants
is comparator
Source null
source pointer
NCT03621982-om-0000#groups/OG003
release id
clinical-indications-draft-1
disease state id
ds-pancreatic-cancer-locally-advanced-06747430
nct id
NCT03621982
outcome key
om-0000
arm key
OG004
arm label
ADCT-301 Monotherapy 80 µg/kg
regimen
Participants received 80 µg/kg ADCT-301 Q3W, IV infusion on Day 1 of each 21-day cycle.
analyzed count
8
analyzed unit
Participants
is comparator
Source null
source pointer
NCT03621982-om-0000#groups/OG004
release id
clinical-indications-draft-1
disease state id
ds-pancreatic-cancer-locally-advanced-06747430
nct id
NCT03621982
outcome key
om-0000
arm key
OG005
arm label
ADCT-301 Monotherapy 100 µg/kg
regimen
Participants received 100 µg/kg ADCT-301 Q3W, IV infusion on Day 1 of each 21-day cycle.
analyzed count
7
analyzed unit
Participants
is comparator
Source null
source pointer
NCT03621982-om-0000#groups/OG005
release id
clinical-indications-draft-1
disease state id
ds-pancreatic-cancer-locally-advanced-06747430
nct id
NCT03621982
outcome key
om-0000
arm key
OG006
arm label
ADCT-301 Monotherapy 125 µg/kg
regimen
Participants received 125 µg/kg ADCT-301 Q3W, IV infusion on Day 1 of each 21-day cycle.
analyzed count
8
analyzed unit
Participants
is comparator
Source null
source pointer
NCT03621982-om-0000#groups/OG006
release id
clinical-indications-draft-1
disease state id
ds-pancreatic-cancer-locally-advanced-06747430
nct id
NCT03621982
outcome key
om-0000
arm key
OG007
arm label
ADCT-301 Monotherapy 150 µg/kg
regimen
Participants received 150 µg/kg ADCT-301 Q3W, IV infusion on Day 1 of each 21-day cycle.
analyzed count
3
analyzed unit
Participants
is comparator
Source null
source pointer
NCT03621982-om-0000#groups/OG007
release id
clinical-indications-draft-1
disease state id
ds-pancreatic-cancer-locally-advanced-06747430
nct id
NCT03621982
outcome key
om-0000
arm key
OG008
arm label
ADCT-301 Combination Therapy 20 µg/kg + Pemb
regimen
Participants received 20 µg/kg ADCT-301 Q3W, IV infusion on Day 1 of each 21-day cycle and Pembrolizumab was administered as a 30 minute IV infusion at a fixed dose of 200 mg (starting 1 hour after the end of the ADCT-301 infusion).
analyzed count
1
analyzed unit
Participants
is comparator
Source null
source pointer
NCT03621982-om-0000#groups/OG008
release id
clinical-indications-draft-1
disease state id
ds-pancreatic-cancer-locally-advanced-06747430
nct id
NCT03621982
outcome key
om-0000
arm key
OG009
arm label
ADCT-301 Combination Therapy 30 µg/kg + Pemb
regimen
Participants received 30 µg/kg ADCT-301 Q3W, IV infusion on Day 1 of each 21-day cycle and Pembrolizumab was administered as a 30 minute IV infusion at a fixed dose of 200 mg (starting 1 hour after the end of the ADCT-301 infusion).
analyzed count
4
analyzed unit
Participants
is comparator
Source null
source pointer
NCT03621982-om-0000#groups/OG009
release id
clinical-indications-draft-1
disease state id
ds-pancreatic-cancer-locally-advanced-06747430
nct id
NCT03621982
outcome key
om-0000
arm key
OG010
arm label
ADCT-301 Combination Therapy 45 µg/kg + Pemb
regimen
Participants received 45 µg/kg ADCT-301 Q3W, IV infusion on Day 1 of each 21-day cycle and Pembrolizumab was administered as a 30 minute IV infusion at a fixed dose of 200 mg (starting 1 hour after the end of the ADCT-301 infusion).
analyzed count
10
analyzed unit
Participants
is comparator
Source null
source pointer
NCT03621982-om-0000#groups/OG010
release id
clinical-indications-draft-1
disease state id
ds-pancreatic-cancer-locally-advanced-06747430
nct id
NCT03621982
outcome key
om-0000
arm key
OG011
arm label
ADCT-301 Combination Therapy 60 µg/kg + Pemb
regimen
Participants received 60 µg/kg ADCT-301 Q3W, IV infusion on Day 1 of each 21-day cycle and Pembrolizumab was administered as a 30 minute IV infusion at a fixed dose of 200 mg (starting 1 hour after the end of the ADCT-301 infusion).
analyzed count
9
analyzed unit
Participants
is comparator
Source null
source pointer
NCT03621982-om-0000#groups/OG011

harms

release id
clinical-indications-draft-1
disease state id
ds-pancreatic-cancer-locally-advanced-06747430
nct id
NCT03621982
harm key
EG000
source section id
NCT03621982-ae
event group key
EG000
event group label
ADCT-301 Monotherapy 20 µg/kg
serious affected
2
serious at risk
3
other affected
3
other at risk
3
frequency threshold
5
collection period
All SAEs and AEs were collected from the time the participant signs the ICF until 30 days after the last dose of study drug up to a maximum of 3 years.
event definition
An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product, which does not necessarily have to have a causal relationship with this treatment.
undenominated note
Source null
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
release id
clinical-indications-draft-1
disease state id
ds-pancreatic-cancer-locally-advanced-06747430
nct id
NCT03621982
harm key
EG001
source section id
NCT03621982-ae
event group key
EG001
event group label
ADCT-301 Monotherapy 30 µg/kg
serious affected
1
serious at risk
5
other affected
5
other at risk
5
frequency threshold
5
collection period
All SAEs and AEs were collected from the time the participant signs the ICF until 30 days after the last dose of study drug up to a maximum of 3 years.
event definition
An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product, which does not necessarily have to have a causal relationship with this treatment.
undenominated note
Source null
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
release id
clinical-indications-draft-1
disease state id
ds-pancreatic-cancer-locally-advanced-06747430
nct id
NCT03621982
harm key
EG002
source section id
NCT03621982-ae
event group key
EG002
event group label
ADCT-301 Monotherapy 45 µg/kg
serious affected
2
serious at risk
5
other affected
5
other at risk
5
frequency threshold
5
collection period
All SAEs and AEs were collected from the time the participant signs the ICF until 30 days after the last dose of study drug up to a maximum of 3 years.
event definition
An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product, which does not necessarily have to have a causal relationship with this treatment.
undenominated note
Source null
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
release id
clinical-indications-draft-1
disease state id
ds-pancreatic-cancer-locally-advanced-06747430
nct id
NCT03621982
harm key
EG003
source section id
NCT03621982-ae
event group key
EG003
event group label
ADCT-301 Monotherapy 60 µg/kg
serious affected
3
serious at risk
5
other affected
5
other at risk
5
frequency threshold
5
collection period
All SAEs and AEs were collected from the time the participant signs the ICF until 30 days after the last dose of study drug up to a maximum of 3 years.
event definition
An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product, which does not necessarily have to have a causal relationship with this treatment.
undenominated note
Source null
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
release id
clinical-indications-draft-1
disease state id
ds-pancreatic-cancer-locally-advanced-06747430
nct id
NCT03621982
harm key
EG004
source section id
NCT03621982-ae
event group key
EG004
event group label
ADCT-301 Monotherapy 80 µg/kg
serious affected
3
serious at risk
8
other affected
8
other at risk
8
frequency threshold
5
collection period
All SAEs and AEs were collected from the time the participant signs the ICF until 30 days after the last dose of study drug up to a maximum of 3 years.
event definition
An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product, which does not necessarily have to have a causal relationship with this treatment.
undenominated note
Source null
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
release id
clinical-indications-draft-1
disease state id
ds-pancreatic-cancer-locally-advanced-06747430
nct id
NCT03621982
harm key
EG005
source section id
NCT03621982-ae
event group key
EG005
event group label
ADCT-301 Monotherapy 100 µg/kg
serious affected
1
serious at risk
7
other affected
7
other at risk
7
frequency threshold
5
collection period
All SAEs and AEs were collected from the time the participant signs the ICF until 30 days after the last dose of study drug up to a maximum of 3 years.
event definition
An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product, which does not necessarily have to have a causal relationship with this treatment.
undenominated note
Source null
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
release id
clinical-indications-draft-1
disease state id
ds-pancreatic-cancer-locally-advanced-06747430
nct id
NCT03621982
harm key
EG006
source section id
NCT03621982-ae
event group key
EG006
event group label
ADCT-301 Monotherapy 125 µg/kg
serious affected
3
serious at risk
8
other affected
8
other at risk
8
frequency threshold
5
collection period
All SAEs and AEs were collected from the time the participant signs the ICF until 30 days after the last dose of study drug up to a maximum of 3 years.
event definition
An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product, which does not necessarily have to have a causal relationship with this treatment.
undenominated note
Source null
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
release id
clinical-indications-draft-1
disease state id
ds-pancreatic-cancer-locally-advanced-06747430
nct id
NCT03621982
harm key
EG007
source section id
NCT03621982-ae
event group key
EG007
event group label
ADCT-301 Monotherapy 150 µg/kg
serious affected
3
serious at risk
3
other affected
3
other at risk
3
frequency threshold
5
collection period
All SAEs and AEs were collected from the time the participant signs the ICF until 30 days after the last dose of study drug up to a maximum of 3 years.
event definition
An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product, which does not necessarily have to have a causal relationship with this treatment.
undenominated note
Source null
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
release id
clinical-indications-draft-1
disease state id
ds-pancreatic-cancer-locally-advanced-06747430
nct id
NCT03621982
harm key
EG008
source section id
NCT03621982-ae
event group key
EG008
event group label
ADCT-301 Combination Therapy 20 µg/kg + Pemb
serious affected
1
serious at risk
1
other affected
1
other at risk
1
frequency threshold
5
collection period
All SAEs and AEs were collected from the time the participant signs the ICF until 30 days after the last dose of study drug up to a maximum of 3 years.
event definition
An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product, which does not necessarily have to have a causal relationship with this treatment.
undenominated note
Source null
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
release id
clinical-indications-draft-1
disease state id
ds-pancreatic-cancer-locally-advanced-06747430
nct id
NCT03621982
harm key
EG009
source section id
NCT03621982-ae
event group key
EG009
event group label
ADCT-301 Combination Therapy 30 µg/kg + Pemb
serious affected
3
serious at risk
4
other affected
4
other at risk
4
frequency threshold
5
collection period
All SAEs and AEs were collected from the time the participant signs the ICF until 30 days after the last dose of study drug up to a maximum of 3 years.
event definition
An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product, which does not necessarily have to have a causal relationship with this treatment.
undenominated note
Source null
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
release id
clinical-indications-draft-1
disease state id
ds-pancreatic-cancer-locally-advanced-06747430
nct id
NCT03621982
harm key
EG010
source section id
NCT03621982-ae
event group key
EG010
event group label
ADCT Combination Therapy 45 µg/kg + Pemb
serious affected
5
serious at risk
10
other affected
10
other at risk
10
frequency threshold
5
collection period
All SAEs and AEs were collected from the time the participant signs the ICF until 30 days after the last dose of study drug up to a maximum of 3 years.
event definition
An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product, which does not necessarily have to have a causal relationship with this treatment.
undenominated note
Source null
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
release id
clinical-indications-draft-1
disease state id
ds-pancreatic-cancer-locally-advanced-06747430
nct id
NCT03621982
harm key
EG011
source section id
NCT03621982-ae
event group key
EG011
event group label
ADCT Combination Therapy 60 µg/kg + Pemb
serious affected
8
serious at risk
9
other affected
9
other at risk
9
frequency threshold
5
collection period
All SAEs and AEs were collected from the time the participant signs the ICF until 30 days after the last dose of study drug up to a maximum of 3 years.
event definition
An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product, which does not necessarily have to have a causal relationship with this treatment.
undenominated note
Source null
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z

quality of life

setting source links

Preserved source evidence · Not medical advice